Pexidartinib Long‐Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors

BACKGROUND: Pexidartinib is approved in the U.S. for tenosynovial giant cell tumors (TGCTs). Herein, we assessed the hepatic safety profile of pexidartinib across patients with TGCTs receiving pexidartinib. MATERIALS, AND METHODS: Hepatic adverse reactions (ARs) were assessed by type and magnitude o...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncologist
Asıl Yazarlar: Lewis, James H., Gelderblom, Hans, van de Sande, Michiel, Stacchiotti, Silvia, Healey, John H., Tap, William D., Wagner, Andrew J., Pousa, Antonio Lopez, Druta, Mihaela, Lin, Chia‐Chi, Baba, Hideo A., Choi, Youngsook, Wang, Qiang, Shuster, Dale E., Bauer, Sebastian
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons, Inc. 2020
Konular:
Sarcomas
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8100574/
https://ncbi.nlm.nih.gov/pubmed/33289960
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13629
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller